The Role of Coffee By-Products in Preventive Gut-Health Strategies: A Narrative Review of Bioactive Composition, Safety and Regulatory Pathways

Introduction: The transition toward a circular bioeconomy has repositioned coffee industry side-streams as high-value reservoirs of functional ingredients. While the roasted bean is the primary commercial product, by-products such as coffee husk and pulp, coffee silverskin (CSS), and spent coffee grounds (SCGs) contain significant amounts of dietary fiber, polysaccharides, and melanoidins that escape upper gastrointestinal digestion. This narrative review critically evaluates these matrices as emerging substrates for gut health modulation, addressing the link between their chemical complexity and prebiotic-like effects. Methods: A narrative synthesis of published literature was developed around four domains: (i) chemical and functional composition; (ii) preclinical and clinical evidence of microbiota modulation; (iii) toxicological profiles and contaminant levels; and (iv) regulatory status within EU and US markets. Evidence was discussed qualitatively to identify translational opportunities and limitations. Discussion: The findings highlight that CSS, coffee husk and pulp, and SCGs converge within a common functional framework where insoluble fibers and “maillardized dietary fibers” (melanoidins) promote the growth of beneficial taxa, including Bifidobacterium spp. and Lactobacillus spp. Specifically, SCG-derived galactomannans and CSS xylan-type structures trigger the biosynthesis of short-chain fatty acids (SCFAs) and reduce colonic pH. Safety assessments indicate that while these materials are susceptible to Ochratoxin A and thermal contaminants like acrylamide, concentrations typically remain within EU regulatory thresholds. However, a significant geographical asymmetry exists in regulation; while coffee husk and pulp is an authorized Novel Food in the EU, CSS and SCGs still face fragmentation and a lack of standardized human interventions. Conclusions: Coffee by-products represent a sustainable platform for the development of gut-health-oriented functional foods. To overcome the identified translational gap, this work proposes an illustrative framework for a future randomized controlled trial (RCT) to investigate gut-health outcomes. Achieving commercial scalability will depend on harmonizing regulatory pathways and ensuring consistent compositional control through advanced bioconversion strategies.